BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
BioAge Labs, Inc.NASDAQ: BIOA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $26K (cash outflow) fell 93.9% year over year, behind the -59.7% change in trailing-twelve-month capital expenditures. Sequentially, it fell 76.8% from the prior quarter. Over 3 fiscal years it compounded at +91.1% a year.
Context
- Capital expenditures amounted to 8.0% of revenue in FY2025.
- Capital expenditures grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -93.9% toward the trailing-twelve-month pace of -59.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (719K) USD
- Year-over-year change
- -96.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (719K) | -96.4% |
| FY2024 | 2024-12-31 | (366K) | -120.5% |
| FY2023 | 2023-12-31 | (166K) | -61.2% |
| FY2022 | 2022-12-31 | (103K) | — |
Capital Expenditures vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -59.7% is the 5th highest of 8, against a peer median of -41.0%.
- Capital expenditures amounts to 3.1% of revenue for BIOA, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$22.56M CAD | +19.6% | +23.0% | 7.3% | |
| LTM Mar 2026 | $6.91M USD | — | -23.5% | 5.1% | |
| LTM Mar 2026 | CA$6.66M CAD | -41.0% | -10.7% | 2.1% | |
| LTM Mar 2026 | $1.16M USD | -4.6% | -65.6% | 2.8% | |
| LTM Mar 2026 | $831K USD | -41.0% | -5.5% | 41.2% | |
| LTM Mar 2026 | $585K USD | -91.7% | -47.2% | 1.5% | |
| LTM Mar 2026 | $444K USD | -79.7% | -20.6% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $319K USD | -59.7% | +91.1% | 3.1% |
| LTM Mar 2026 | $296K USD | -62.3% | -57.9% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding BIOA) | — | -41.0% | -22.0% | 3.9% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.